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Abstract: Efficient synthesis of NAD+ is critical to maintaining cell viability in all organs of the body. However, little is known of
the pathway(s) by which cells of the central nervous system produce NAD+. The aim of this study was to investigate the relationship,
between tryptophan degradation via the kynurenine pathway (KP) and de novo NAD+ synthesis in human astrocytes, a major cell type
within the brain. In this study we observed that inhibition of single enzymes of the KP resulted in significant decreases in NAD+ levels in
astroglial cells after a 24 hr period. We also observed that astrocytes cultured in media deficient in tryptophan, nicotinic acid and nicotinamide resulted in a 50% decrease in NAD+ levels after 24 hrs. This decrease in NAD+ was partially restored by supplementation of the
culture media with either tryptophan or kynurenine, or nicotinic acid or with supply of the salvage pathway precursor nicotinamide.
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Introduction

Nicotinamide adenine dinucleotide (NAD+), as the
parent molecule for the pyridine family of nucleotides,
(NADH, NADP and NADPH) is an important
coenzyme enabling electron transfer in the oxidative
production of ATP and for hydride ion transfer in
many enzyme reactions. Depleted mitochondrial
NAD+ impairs respiration and ATP synthesis resulting
in energy crisis and cell death.1 More recently NAD+
has also been identified as a primary substrate for
other important enzymes including poly (ADPribose) polymerase (PARP) and the sirtuin family of
de-acetylase enzymes. PARP is a nuclear enzyme,
activated by DNA strand breaks that are involved in
DNA repair and maintenance of genomic integrity.
PARP uses up NAD+ to make ADP ribose polymers.
An increase in DNA damage (often due to oxidative
stress) can rapidly deplete the cell of NAD+ resulting
in reduced ATP production and cell death.2,3 NAD+ is
also a substrate for a relatively new class of NAD+
dependent de-acetylase enzymes called the sirtuins
(SIRT1-7). Sirtuin enzymes consume NAD+ in the
process of removal of acetyl groups from histone
and non-histone moieties. Sirtuin targets consist
of a variety of transcription factors and proteins
involved in important processes, such as stress resistance and cell survival.4 Enhancing sirtuin activity
has been shown to promote longevity in a range of
organisms.5 As NAD+ plays a central role in these
cellular systems, synthesis of NAD+ is essential to

ensuring the health of the cell and associated organ
systems.
De novo synthesis of NAD+ from tryptophan
through the kynurenine pathway (KP) has been studied
in the periphery and established as a primary source
of NAD+, in the kidney and liver.6 We have previously
reported that in the rat central nervous system (CNS),
NAD+ concentrations can be regenerated in astrocytes
using nicotinic acid, nicotinamide or quinolinic acid7
and that some downstream KP metabolites can affect
NAD+ levels in human astrocytes.8 However the
relative importance of KP and/or salvage pathway
(Fig. 1) metabolism to NAD+ synthesis in primary
human brain cells is yet to be clarified. We have
earlier reported that human astrocytes are deficient
in one of the enzymes of the tryptophan to NAD+
metabolic cascade.9 It is therefore not clear whether
tryptophan catabolism is involved in NAD+ synthesis
in these cells. Clarification of this question is important as NAD+ depletion is becoming increasingly recognised as a cause of cell death in CNS inflammatory
and degenerative disorders.10
The aim of this study was therefore to investigate
the relationship, between kynurenine pathway (KP)
metabolism and de novo NAD+ synthesis in astrocytes,
the most numerous cell type of the CNS. Results
from this study, showing the dependence of CNS
cells on KP metabolism for NAD+ synthesis, implies
that the KP could represent a significant clinical and
therapeutic target.
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Figure 1. Schematic of NAD+ Biosynthesis; de novo and Salvage Pathways. (a) Indoleamine 2,3 dioxygenase 1 (1&2), (b) kynurenine formylase,
(c) kynurenine 3-hydroxylase, (d) kynureninase, (e) 3-hydroxyanthranilic acid oxidase, (f) quinolinic acid phosphoribosyl transferase, (g) nicotinic acid
phosphoribosyltransferase (h) nicotinic acid mononucleotide adenylyltransferase (i) Glutamine dependent NAD+ synthetase, (j) Poly (ADP ribose)
polymerase (PARP), (k) nicotinamide phosphoribosyltransferase OR pre-B-cell enhancing factor, (l) nicotinic acid mononucleotide adenylyltransferase.
(α) This reaction proceeds non-enzymatically.
Abbreviations: NIC, nicotinic acid; NAMN, nicotinic acid mononucleotide; NAAD, nicotinic acid adenine dinucleotide; NAD, nicotinamide adenine
dinucleotide; NAM, nicotinamide; NMN, nicotinamide mononucleotide.
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NAD synthesis from KP

Materials and Methods
Reagents and chemicals

All cell culture media and supplements were purchased
from Invitrogen (Australia) unless otherwise stated.
All reagents and chemicals used in experiments
were purchased from Sigma Aldrich Chemical Co.
(Australia) unless otherwise stated.

Cell cultures

Human primary astrocytes were grown in uncoated
flasks (Falcon) and maintained in complete media
(cRPMI), which contains RPMI 1640 media supplemented with 10% foetal bovine serum (FBS), 1%
2 mM glutamine (Sigma Aldrich, Australia) and 1%
penicillin/streptomycin (Sigma Aldrich, Australia).
As part of its normal commercial formulation cRPMI
contains 24 µM tryptophan and 8 µM nicotinamide.
The cell medium was changed twice a week, and all
cell cultures were kept incubated at 37 °C in 5% CO2.9
A day prior to experimental treatments, cultures
were trypsinised (Trypsin 0.25%) and seeded at
desired cell density, into 24 well plates (Falcon).

Nad+ precursor depleted RPMI

Depleted RPMI (dRPMI) was prepared using a
standard mix formula for RPMI that included all
nutrients except tryptophan (TRYP) and nicotinamide
(NAM). Note that standard RPMI does not contain
nicotinic acid (NIC) or kynurenine (KYN).
The dRPMI medium containing 10% FBS, 1%
2 mM glutamine (Sigma Aldrich, Australia) and 1%
penicillin/streptomycin (Sigma Aldrich, Australia)
was supplemented as required with the addition
of substrates TRYP (25 µM), KYN (25 µM) NAM
(10 µM) or NIC (10 µM). The concentrations chosen
for TRYP and NAM supplementation correspond
to that found in the commercially prepared RPMI
(cRPMI). As KYN is not present in RPMI media
this upstream metabolite was added at a concentration comparable to TRYP, which has been shown to
increase in the culture medium of stimulated astroglial cells.13 NIC (the acid form of vitamin B3) is also
not normally present in RPMI media and was added
at the same concentration as its amide form, NAM
to allow direct comparison. All supplements were
prepared as sterile solutions in purified (.10 mΩ)
water).
International Journal of Tryptophan Research 2010:3

Nad+ precursor supplementation

Astrocytes were seeded into a 24-well culture plate at
a density of 1 × 105 cells/ml in and left to equilibrate
in 5% CO2 at 37 °C in complete RPMI (cRPMI) for
24 hr. The culture medium was then aspirated and
each well was washed twice with warm phosphate
buffered saline (PBS) before addition of 1 ml of fresh
dRPMI (containing no TRYP, NAM or NIC). Selected
NAD+ substrates TRYP (25 µM), KYN (25 µM)
NAM (10 µM) or NIC (10 µM) were then added to
appropriate cultures for 24 hrs before analysis.

Kp enzyme inhibition

Human primary astrocytes were plated into 24-well
plates at a density of 1 × 105 cells/ml in cRPMI and left
to equilibrate for 24 hours before treatment. Cultured
medium was aspirated from each well, washed twice
with warm phosphate buffered saline (PBS), before
addition of 1 ml of fresh cRPMI followed by addition
of specific inhibitors (Table 1) for 24 hrs.
NAD+ analysis
Cultured medium was aspirated from each well.
The cells were washed twice with PBS, before
being homogenised by sonication in 500 µl of PBS
(containing 12 mM nicotinamide as a PARP inhibitor).
Quantification of NAD+ (H) in the cell was measured
using the Thiazolyl blue microcycling assay11 adapted
to a 96-well format.7

Total protein assay

Cultured medium was removed from each well
and the cells were washed twice with PBS, before
Table 1. Inhibitors used in the experiments.
Inhibitor

Concentration
(mM)

Action/notes

1-methyl-Tryptophan
(1-MT)δ
3-ethoxy-β-carboline
(3-EBC)ψ

1

Phthalic Acid
(PHTH)χ

0.04

Competitive
IDO inhibitor
Noncompetitive
IDO inhibitor
‘Dead-end’
inhibitor of
QPRT

0.2

Notes: δPrevious studies have shown maximal IDO1 inhibition using
ψ
1 mM 1-MT.15 We have previously shown that 0.2 mM 3-EBC results in a
maximal decrease in IDO1 activity in astroglial cells without measurable
toxicity.13 χDose response analysis showed a maximal effect using PHTH
at 0.04 mM (unpublished data).
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Statistical analysis

For all culture samples, significant differences between
treatment groups, at P , 0.05 level of significance,
were determined using One-way ANOVA and
Dunnett’s multiple comparison test. All results are
represented as mean ± standard error mean.

Results
Involvement of KP enzymes in de novo
NAD+ synthesis

To determine whether tryptophan catabolism via the
KP played a role in NAD+ synthesis, we used small
molecule inhibitors that reduced the activity of critical
enzymes at the beginning and end of the KP.
Inhibition of the initial rate limiting enzyme
indoleamine 2,3 dioxygenase (IDO1) with either the
competitive inhibitor, 1-methyl tryptophan (1-MT) or
the non-competitive inhibitor, 3-ethoxy-β-carboline
(3EBC) significantly decreased intracellular NAD+
by 14% and 26% respectively after 24 hrs. In a similar fashion, inhibition of the downstream KP enzyme,
quinolinic acid phosphoribosyl transferase (QPRT)
with the dead-end inhibitor phthalic acid (PHTH)
resulted in a significant 29% decrease in intracellular
NAD+ levels after 24 hrs (Fig. 2).

Importance of de novo and salvage
pathway precursors to NAD+ synthesis

To help verify that the results obtained for enzyme
inhibition were specific to KP metabolism, we tested
whether the removal of KP or salvage pathway
precursors (i.e. tryptophan, nicotinic acid and nicotinamide) from the incubation medium affected cellular
NAD+ levels.
We found that in the absence of all of these
precursors a significant decrease of 50% in intracellular NAD+ levels after 24 hrs was observed (Fig. 3).
Subsequent supplementation of the incubation
medium with the upstream KP precursor tryptophan
alone, increased NAD+ levels by 75% within 24 hrs
154
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Figure 2. Effect of inhibition of selected KP enzymes on NAD+ levels
in primary human astrocytes. Cellular NAD+ levels were significantly
reduced in primary human astrocyte cultures (1  105 cells/ml) following
treatment with: The competitive IDO inhibitor 1-methyl tryptophan (1-MT,
1 mM) or the non-competitive IDO inhibitor, 3-ethoxy, β carboline (3-EBC,
0.2 mM) or the QPRT inhibitor phthalic acid (PHTH, 0.04 mM) for 24 hrs.
Note: *P  0.05 compared to control, (n = 4 for each treatment group).

compared to control. Addition of nicotinic acid to
the culture medium also increased NAD+ levels
significantly by 54% after 24 hrs (Fig. 3). Though
an apparent increase in NAD+ was observed with
kynurenine and nicotinamide supplementation, these
did not reach statistical significance (Fig. 3).

Discussion

We have previously shown that KP metabolism is
linked to the maintenance of NAD+ levels in murine
primary astrocytes and human and murine cell
lines.7,12,13 However, following the observation that
primary human astrocytes do not express the KP
enzyme, kynurenine 3-hydroxylase,9 we were unsure
whether these cells could efficiently use tryptophan
for NAD+ synthesis. Using the dual approach of
enzyme inhibition and NAD+ substrate depletion, we
investigated the role of the KP and salvage pathway
metabolism in the maintenance of NAD+ concentrations in primary human astrocytes.
In the present study, we observed that intracellular
NAD+ levels decreased significantly following inhibition of either the initial or downstream KP enzymes
IDO1 or QPRT, respectively (Fig. 2). These results
are consistent with our previous findings showing a
clear relationship between IDO activity and NAD+
International Journal of Tryptophan Research 2010:3
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Figure 3. Effect of substrate availability on cellular NAD+ levels in primary
human astrocytes. Primary human astrocytes grown in either dRPMI
(RPMI with 10% FBS without the NAD+ precursors tryptophan, nicotinic
acid or nicotinamide) or cRPMI (complete RPMI with 10% FBS containing
tryptophan and nicotinamide) ± addition of the specific NAD+ precursors
tryptophan (TRYP, 25 µM), nicotinic acid, (NIC, 10 µM), nicotinamide
(NAM, 10 µM) or kynurenine (KYN, 25 µM) for 24 hrs resulted in a
significant increase in NAD+ levels.
Note: *P  0.05 compared to control (n = 3–4 for each treatment group).

levels in a human astroglioma cell line.13 Supporting
these results, we also observed that intracellular
NAD+ levels decreased significantly after 24 hrs in the
absence of either KP metabolites or salvage pathway
substrates in the incubation medium (Fig. 3).
The subsequent regeneration of NAD+ from TRYP,
KYN, NIC or NAM (Fig. 3) strongly suggests the
metabolic use of these precursors in the production
of NAD+.
This result is similar to our previous reports showing
that quinolinic acid or nicotinic acid or nicotinamide
were able to regenerate NAD+ after oxidative stress in
murine primary astrocytes7. In the present study the
observation that primary human astrocytes regenerated
NAD+ more efficiently from NIC than NAM when supplied in equimolar concentrations (Fig. 3) is indicative
of preferred metabolism from this source. This is again
consistent with our previous report in murine primary
astrocytes showing NIC was also more efficient at promoting NAD+ regeneration than the amide.7
Taken together these results support the hypothesis
that the KP is an important route for NAD+ synthesis
in primary human astroglial cells. As this occurs in
International Journal of Tryptophan Research 2010:3

spite of the previously reported absence of kynurenine
3-hydroxylase,9 the progress around this blockade to
NAD+ most likely occurs via efficient non-enzymatic
hydroxylation of anthranilic acid to 3-hydroxyanthranilic acid (Fig. 1). This is consistent with studies
done some time ago by Henderson et al who reported
that kynurenine could be converted to niacin (NAD+)
in kidney and liver tissue through non-enzymatic
hydroxylation.16
Importantly, though tryptophan catabolism via the
KP clearly results in NAD+ production, significant
synthetic capacity is also possible via nicotinic acid
or nicotinamide and the salvage pathway (Fig. 3).
With growing interest in IDO1 inhibition as a
therapeutic target14 coupled with the fact that maintaining
NAD+ levels is an essential part of organ health10 characterisation of NAD+ metabolism in other cells of the
CNS such as neurons and microglia are needed. Further
research is also required to confirm whether NAD+
levels can be effectively maintained when IDO1 or
other KP enzymes are inhibited by concurrent addition
of NIC or salvage pathway precursors such NAM.
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